bs-1185R [Primary Antibody]
TRAF3 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TRAF3

Immunogen Range: 101-200/568


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 7187

Swiss Prot: Q13114

Source: KLH conjugated synthetic peptide derived from human TRAF3

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Regulates pathways leading to the activation of NF-kappa-B and MAP kinases, and plays a central role in the regulation of B-cell survival. Part of signaling pathways leading to the production of cytokines and interferon. Required for normal antibody isotype switching from IgM to IgG. Plays a role T-cell dependent immune responses. Plays a role in the regulation of antiviral responses. Is an essential constituent of several E3 ubiquitin-protein ligase complexes. May have E3 ubiquitin-protein ligase activity and promote 'Lys-63'-linked ubiquitination of target proteins. Inhibits activation of NF-kappa-B in response to LTBR stimulation. Inhibits TRAF2-mediated activation of NF-kappa-B. Down-regulates proteolytic processing of NFKB2, and thereby inhibits non-canonical activation of NF-kappa-B. Promotes ubiquitination and proteasomal degradation of MAP3K14.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
FCM(1:20-100)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 62


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Yi Zhuet al. MicroRNA MiR-27a-5p Alleviates the Cerulein-Induced Cell Apoptosis and Inflammatory Injury of AR42J Cells by Targeting Traf3 in Acute Pancreatitis. Inflammation. 2020 Oct;43(5):1988-1998.Read more>>
  • Wanwan Zhang. et al. Nectin4 antagonises type I interferon production by targeting TRAF3 for autophagic degradation and disrupting TRAF3-TBK1 complex formation. INT J BIOL MACROMOL. 2022 Oct;218:654Read more>>
  • Yuan Qi. et al. Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma. BRAZ J MED BIOL RES. 2023 Jul;56:e12638Read more>>
VALIDATION IMAGES

Human Jurkat cells probed with TRAF3 Polyclonal Antibody, Unconjugated (bs-1185R) at 0.2ug for 30 minutes followed by incubation with a PE Conjugated secondary for 30 minutes compared to control cells (blue), secondary only (light blue) and isotype control (orange).


Formalin-fixed and paraffin embedded human gastric carcinoma tissue labeled with Anti-TRAF3/CD40bp Polyclonal Antibody, Unconjugated (bs-1185R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Formalin-fixed and paraffin embedded mouse lymphoma tissue labeled with Anti-TRAF3/CD40bp Polyclonal Antibody, Unconjugated (bs-1185R) at 1:200 followed by conjugation to the secondary antibody and DAB staining


Paraformaldehyde-fixed, paraffin embedded Mouse brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with TRAF3 Polyclonal Antibody, Unconjugated (bs-1185R) at 1:400 overnight at 4°C, DAB staining.